Mass Effect in Progressive Multifocal Leukoencephalopathy

Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy

“…T1-weighted MRI will often show some hypointensity and CT scanning may also demonstrate hypodensity but with understandably lower sensitivity. Mass effect can be seen but is infrequent and always mild in severity [26,27]. Enhancement, usually faint, may be seen in as many as one quarter of patients at presentation or with immune improvement and response to the infection [28,29].…”

Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy

“…T1-weighted MRI will often show some hypointensity and CT scanning may also demonstrate hypodensity but with understandably lower sensitivity. Mass effect can be seen but is infrequent and always mild in severity [26,27]. Enhancement, usually faint, may be seen in as many as one quarter of patients at presentation or with immune improvement and response to the infection [28,29].…”

Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy

“…T1-weighted MRI will often show some hypointensity and CT scanning may also demonstrate hypodensity but with understandably lower sensitivity. Mass effect can be seen but is infrequent and always mild in severity [26,27]. Enhancement, usually faint, may be seen in as many as one quarter of patients at presentation or with immune improvement and response to the infection [28,29].…”

Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy

“…T1-weighted MRI will often show some hypointensity and CT scanning may also demonstrate hypodensity but with understandably lower sensitivity. Mass effect can be seen but is infrequent and always mild in severity [26,27]. Enhancement, usually faint, may be seen in as many as one quarter of patients at presentation or with immune improvement and response to the infection [28,29].…”